IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to four newly hired employees on August 28, 2025. The Compensation Committee approved non-qualified stock options to purchase 139,800 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options have an exercise price of $24.93 per share, matching IDEAYA's closing price on the grant date. The options feature a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment.

News Market Reaction – IDYA

-1.52%

1 alert

-1.52% Session close to close

$2.15B Market Cap

0.7x Rel. Volume

In the Aug 29 session, IDYA declined 1.52%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 28, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 139,800 shares of the Company's common stock to four newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $24.93 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302541781.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What is the exercise price of IDYA's new stock options granted on August 28, 2025?

The stock options were granted with an exercise price of $24.93 per share, equal to IDEAYA's closing price on The Nasdaq Global Select Market on the grant date.

How many shares of IDYA stock were granted in the inducement options?

IDEAYA Biosciences granted options to purchase an aggregate of 139,800 shares of the company's common stock to four newly hired employees.

What is the vesting schedule for IDEAYA Biosciences' August 2025 inducement stock options?

The options vest over four years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment.

Why did IDEAYA Biosciences (IDYA) issue these stock options?

The stock options were granted as inducement awards under Nasdaq Listing Rule 5635(c)(4) to attract new employees who were not previously employed by IDEAYA.